Decision Date:
November 2022


RED: NICE TA924 - Tirzepatide for treating type 2 diabetes. RED recommendation as holding position for TA compliance. ICB commissioned (Decision date November 2023)

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app